A clear UK comparison of oral weight loss pills and injectable GLP-1 treatments, covering clinical evidence, practical differences, side effects, costs and what is currently available.
For most of the past three years, the question of which GLP-1 weight loss treatment to choose has been a choice between two injections: Mounjaro or Wegovy.
That is changing. With oral semaglutide 25mg now FDA-approved in the US, orforglipron approved in April 2026, and both under MHRA review in the UK, the pill versus jab question is moving from hypothetical to genuinely practical.
This comparison covers the clinical evidence, the practical differences, and the honest trade-offs that anyone considering a weight loss treatment in the UK in 2026 needs to understand — both for treatments currently available and for what is coming.
The bottom line: for patients who can tolerate injections, the injectable options currently available in the UK still have stronger evidence for greater average weight loss.
But the emerging oral options are closing the gap quickly, and for needle-averse patients, the decision is more nuanced than the headline numbers suggest.
UK availability note: oral semaglutide 25mg and orforglipron are not yet licensed in the UK as of May 2026. Injectable Mounjaro and Wegovy are the currently available UK options through appropriate prescribing routes.
A simple visual breakdown of the key points covered in this guide.
| Medication | Administration | Average weight loss | UK licensed | Estimated UK cost | Common side effects | Needle required | Storage | Dosing schedule |
|---|---|---|---|---|---|---|---|---|
| Mounjaro injection | Weekly self-injection pen | 20.2% in SURMOUNT‑5 | Yes | Approx. £149 to £375 per month | Nausea, vomiting, diarrhoea, constipation | Yes | Refrigerate before first use | Weekly, same day |
| Wegovy injection | Weekly self-injection pen | 13.7% to 20.7% in STEP studies | Yes | Approx. £130 to £295 per month | Nausea, vomiting, diarrhoea, constipation | Yes | Refrigerate before first use | Weekly, same day |
| Oral semaglutide 25mg | Daily pill with empty stomach and fasting rules | Approximately 17% in OASIS 4 | Under MHRA review | To be confirmed | Similar to injectable semaglutide | No | Room temperature | Daily, empty stomach |
| Orforglipron | Daily pill, any time, with or without food | Approximately 7% to 9% at 36 weeks | Under MHRA review | To be confirmed | Mainly mild to moderate gastrointestinal effects | No | Room temperature | Daily, flexible timing |
Orforglipron data is based on 36-week phase 3 results. Longer-term data and higher-dose results are still pending.
The honest answer is that it depends which pill and which injectable option you are comparing.
Injectable Mounjaro currently has the strongest weight loss evidence among the approved options. The supplied article notes 20.2% average body weight reduction over 72 weeks in SURMOUNT‑5.
Oral semaglutide 25mg comes closer than earlier oral options, but still sits below the Mounjaro figure in the supplied article.
Wegovy and oral semaglutide use the same active ingredient in different forms and dosing routes.
Based on the supplied article, oral semaglutide 25mg appears competitive against standard-dose injectable semaglutide, though availability remains the key issue in the UK.
Orforglipron may be attractive because it can be taken as a pill without the fasting rules associated with oral semaglutide.
However, the current weight loss data quoted in the article remains below both injectable options, with longer-term evidence still awaited.
Some patients value convenience and no needles, while others prioritise stronger evidence, weekly dosing and currently available UK treatment options.
For people with needle anxiety or needle phobia, a weekly injection can be a genuine barrier. An oral option removes that barrier completely.
Injectable options usually have refrigeration requirements before first use. Oral options are expected to be easier to store and easier to carry while travelling.
A pill can feel more private than storing injection pens, needles and sharps disposal items at home or while travelling.
Orforglipron may offer a practical advantage because it is expected to be taken with or without food, while oral semaglutide has stricter dosing requirements.
This is the biggest practical point. Mounjaro and Wegovy injections are available through appropriate UK prescribing routes today. Oral GLP-1 weight loss pills are not currently licensed in the UK.
The evidence base for injectable treatments is more mature, with large clinical trials and several years of prescribing experience behind them.
UK clinicians and providers have more real-world experience supporting patients through nausea, dose changes and early treatment side effects with injectable GLP-1 treatments.
A weekly injection may be easier for some people than remembering a daily pill, especially if the pill has strict timing or fasting rules.
Not substantially, based on the supplied article. GLP-1 side effects are mainly linked to the way the medicine works in the body, not only the way it is taken.
The most common side effects across injectable and oral GLP-1 treatments include nausea, vomiting, diarrhoea and constipation. These effects are often more noticeable during the early weeks of treatment and during dose increases.
Oral options avoid injection-site reactions such as bruising or irritation, but the gastrointestinal side effect profile may still be similar.
The supplied article states that injectable Mounjaro currently starts from around £149 per month for the starter dose and can rise to around £300 to £375 per month at higher doses.
Wegovy is listed as starting from around £130 per month, with higher-dose monthly costs around £295.
UK pricing for oral semaglutide 25mg and orforglipron has not yet been confirmed, so patients should avoid assuming that oral options will definitely be cheaper.
CompareTheJab lists UK weight-management service providers with a focus on pricing, consultation quality, safety checks, support and transparency.
No GLP-1 oral weight loss pill is currently licensed in the UK according to the supplied article. Other oral weight loss medicines exist, but they work differently and are not the same as GLP-1 treatments.
Current evidence suggests that injectable options still have stronger average weight loss data overall, especially Mounjaro. Oral semaglutide 25mg appears closer to injectable efficacy than earlier oral options, but UK availability remains limited.
Broadly, yes. Nausea, vomiting, diarrhoea and constipation are common GLP-1 class side effects whether the medicine is taken as a pill or injection. Oral options avoid injection-site reactions.
Switching may be possible, but it should be managed by a qualified prescriber. Dosing, timing and any washout period would need clinical guidance.
Based on the supplied article, oral semaglutide 25mg currently shows the strongest weight loss results among the oral options approaching UK approval. Orforglipron may offer practical advantages because of its flexible dosing.
This article is for informational purposes only and does not constitute medical advice. CompareTheJab is an independent comparison website and is not a medical service. Always consult a qualified healthcare professional before starting, stopping or switching any medication.
Clinical trial data, regulatory status and pricing information can change. Information is presented as current according to the supplied article dated May 2026. Some links on this website may be affiliate links. Editorial content should remain separate from commercial relationships.
Medically reviewed: May 2026. Next review: August 2026.